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Scientific summary Background
Multiple sclerosis (MS) is a chronic inflammatory and neurodegenerative disorder in which the clinical features, including presentation, disease course and rates of accumulation of neurological disability, demonstrate high degrees of individual variation. The majority of patients (≈85%) will present with a relapsing-remitting (RR) disease course, typified by acute relapses ('attacks') followed by periods of remission (recovery). Over time, relapsing-remitting multiple sclerosis (RRMS) can convert to secondaryprogressive multiple sclerosis (SPMS), which is associated with a progressive course (gradual worsening) with or without superimposed relapses. The variability in the MS disease course can cause anxiety and frustration for patients, families and health-care professionals alike. Better prediction of disease progression represents a major unmet need in MS. A realistic prognosis would be of considerable importance to patients and would also help to inform therapeutic and management choices. This is particularly relevant when recent developments in therapeutics are hoped to have a significant positive impact on the natural history of MS, but there are also clearly costs in terms of serious adverse events. Patients and their carers increasingly request access to relevant prognostic information to help plan both professional and family life decisions.
There is no cure for MS, but available treatment includes disease-modifying therapies (DMTs), also known as 'immunomodulatory agents', which are currently licensed only for patients with relapsing-onset MS (RR or SPMS). In 2002, there were four licensed DMTs: two forms of interferon beta-1a [Avonex ® (Biogen Idec Ltd) and Rebif ® (Merck Serono Ltd), with high-and low-dose formulations available, 44 µg and 22 µg, respectively], one form of interferon beta-1b [Betaferon ® (Bayer Plc)] and glatiramer acetate [Copaxone ® (Teva UK Ltd)] (first generation). At that time, the UK's National Institute for Health and Care Excellence appraised the evidence for cost-effectiveness of these DMTs and concluded that they were not costeffective over a 10-or 15-year period. However, they also concluded that, because the relevant clinical trials were based on only short-term outcomes, there was not enough information to assess the longerterm implications of these DMTs. To try to address these concerns, the UK MS risk-sharing scheme (RSS) was established in 2002. Under the scheme, the UK's Department of Health agreed to pay for the DMTs, conditional on treated patients being included in a 10-year monitoring study aiming to assess progression of the disease. The monitoring study aimed to compare progression of MS within this treated group of patients with progression in an untreated cohort. Initially, a cohort of untreated patients from London, Ontario, Canada, were selected [being a subset of 314 patients judged to have fulfilled the Association of British Neurologists (ABN) criteria, from the London, Ontario, cohort of 1043 patients recruited between 1972 and 1984] . The first report from the UK MS RSS based on the 2-year follow-up data was unable to find evidence for their cost-effectiveness, but the authors were hesitant in drawing any firm conclusions because of methodological limitations. The main concerns raised related to the use of the London, Ontario, cohort, which included only patients with stable or deteriorated disability scores; in contrast, in real-life clinical practice, scores naturally fluctuate and can also improve. This use of the London, Ontario, cohort forced a complex algorithm to be used in the analysis, creating an artificial 'no-improvement' rule. This caused multiple problems, resulting in uncertainty in the findings, with the sensitivity analysis revealing qualitatively different results from the main analysis (suggesting that the DMTs might actually have a beneficial effect). The authors noted that, given potential secular trends in the natural history of MS, a more contemporary cohort would be preferable, and that modelling approaches other than the Markov model could be used.
We set out to develop and validate models that would facilitate predicting disease progression in patients with RR-onset MS. We then aimed to use these models to estimate the impact of the current first generation of disease-modifying drugs on disease progression in MS. Objectives 1. To develop and apply multilevel models to repeated measures (longitudinal) data on disease progression in patients with relapsing-remitting onset MS (including those who go on to reach SPMS) in two different countries with similar health systems, by accessing the University of Wales Multiple Sclerosis (UoWMS) and British Columbia Multiple Sclerosis (BCMS) databases. 2. To use these models to determine average progression trajectory [as measured by the Expanded Disability Status Scale (EDSS)], individual deviations from the average and accuracy of prediction of individual trajectories. 3. To examine the impact of 'informative censoring' using joint modelling of the EDSS trajectory and time to censoring (whether censored because a patient drops out or because they cease to contribute to the analysis when they start a DMT) and, if necessary, use multiple imputation methods as part of a sensitivity analysis. 4. To apply the multilevel model developed above to data from the 6-year follow-up of the UK MS RSS cohort to estimate average progression trajectory, individual deviations from the average and average difference between individual progression trajectories in the UK MS RSS and progression predicted by the BCMS model and, thus, to estimate the effect of the MS drugs on progression. 5. To apply patient-derived utilities to the observed EDSS score in the UK MS RSS cohort and to the EDSS score predicted under the natural history model, and thus to estimate the difference in utility that may be a result of DMT. Utility is a measure of society's perception of the quality of life of a patient in a given state of health. A utility of 1 represents perfect health while a utility of 0.5 implies that, on average, people would regard 12 months of life in that health state as equally preferable to 6 months of life in perfect health.
Methods
We used the Welsh database (UoWMS) for exploratory modelling, then developed the final natural history model using the BCMS database and validated its ability to predict progression in UoWMS patients. Patients with RRMS or SPMS were included in the models once they had met the ABN criteria for eligibility for starting DMT. We operationalised these criteria as age ≥ 18 years, EDSS score ≤ 6.5 points and occurrence of at least two relapses in the previous 2 years. From the BCMS cohort we included only patients who reached ABN eligibility between 1980 and 1997, who had definite MS and a minimum of two EDSS scores at least 9 months apart. We excluded EDSS scores taken during a relapse, or when disability was affected by other factors considered largely unrelated to MS (e.g. hip fracture), or once a patient started immunomodulatory drug treatment. Multilevel models were used to model the trajectory of EDSS scores with time, and to take account of the fact that observations of EDSS score (level 1) are nested within individuals (level 2), and that EDSS score observations within the same individual are likely to be correlated. These models allow EDSS trajectory to vary between individuals, and observed EDSS score to vary about this trajectory within individuals. The model developed for the natural history of MS (using the BCMS cohort) was used to predict EDSS score for patients in the UoWMS cohort. The final model (developed using the BCMS cohort) was applied to the UK MS RSS cohort, and used to estimate the EDSS score had the cohort not been treated. This predicted 'natural history' EDSS score was compared with the observed EDSS score at 6 years' follow-up in this treated cohort, to estimate the effect of treatment.
Results
First, we were able to show model replication between the two geographically distinct cohorts, which is remarkable in such a variable disease as MS (aims 1 and 2). Whether or not the time axis was time since onset or time since ABN eligibility, the Welsh and British Columbia cohorts gave rise to models with the same functional form and similar parameters. For example, when modelling EDSS score against time since onset, the models from the UoWMS and BCMS cohorts showed a significant difference only in the level 1
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The coefficients from the model for one cohort could be used to predict EDSS score for patients from the other cohort by conditioning on the first EDSS score observed for an individual. The accuracy of these predictions will always be limited by measurement error associated with the EDSS score. Thus, when using the BCMS model to predict EDSS score for individual patients in the UoWMS cohort, conditional on their first EDSS score observation, 90% of the predictions lay within -2.84 to 1.56 points of the true EDSS score value. Although the accuracy of these predictions may not be sufficiently good for predicting at an individual level for clinical purposes, these results provide strong evidence of the ability to use one cohort of MS patients as a non-randomised comparison group for another.
We confirmed several factors as being related either to average EDSS score or to rate of change of EDSS score over time. Those who were older at MS onset tended to have higher EDSS scores and slightly greater rates of increase in EDSS score over time. Those with SPMS had a higher EDSS score at ABN eligibility (although no obvious difference in progression), as did those with more relapses in the 2 years prior to ABN eligibility. Women had lower EDSS scores, on average, than men, but again with no obvious differences in EDSS trajectory. The estimates of these associations were consistent between the two cohorts.
Our study indicates that EDSS trajectory can be modelled using multilevel models. In all models, there was no strong evidence of non-normality of residuals and, therefore, no need to consider further transformations of EDSS score. We also found no evidence against the use of the EDSS score as a continuous variable, rather than an ordinal outcome (as it was designed), in that the models with EDSS score as a continuous outcome appeared to predict EDSS score well. There was evidence that intraindividual variability in EDSS score was greater for lower EDSS scores, as previously suggested.
Using the BCMS cohort natural history model to predict what EDSS score would have been had a treated cohort (the UK MS RSS) not been treated leads to the conclusion that the UK MS RSS may have a slightly lower mean EDSS score [by 0.59 points, 95% confidence interval (CI) 0.54 to 0.64 points] at 6 years post treatment (aim 3). Using patient-derived utility scores (on a scale of 0 to 1), the UK MS RSS showed a slightly higher utility score at 6 years' follow-up than that predicted using the natural history cohorts (by 0.04 utility points, 95% CI 0.036 to 0.047 utility points) (aim 4).
Conclusions
Our major finding was the ability to develop and then validate a model of disease progression in two geographically distinct MS cohorts (aim 1). Our trajectory of disability (EDSS score) over time was similar in the Welsh and BCMS cohorts, with no evidence of informative censoring (aim 2). This is a significant finding given the high variability of progression in MS and the often-differing findings from the MS natural history studies published to date. This provides evidence that using appropriately collected disability data (EDSS score) and advanced modelling, the progression of MS can be modelled, and that models from one population can be used to provide information about a different population of MS patients. Using this approach, we concluded that EDSS score and EDSS score-based utility progression in the treated UK MS RSS cohort was slower than that predicted by the natural history model (aims 3 and 4). Further research into the ability of these models to provide useful information to individuals (rather than populations) is needed before they can be used to provide prognostic information and help to decide on treatment options.
